Galectin-9 Signaling through TIM-3 Is Involved in Neutrophil-Mediated Gram-Negative Bacterial Killing: An Effect Abrogated within the Cystic Fibrosis Lung

Isabel Vega-Carrascal, David A. Bergin, Oliver J. McElvaney, Cormac McCarthy, Nessa Banville, Kerstin Pohl, Mitsuomi Hirashima, Vijay K. Kuchroo, Emer P. Reeves and Noel G. McElvaney

*J Immunol* 2014; 192:2418-2431; Prepublished online 29 January 2014; doi: 10.4049/jimmunol.1300711
http://www.jimmunol.org/content/192/5/2418

---

**Why The JJ?**

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

---

**References**  This article **cites 81 articles**, 34 of which you can access for free at: [http://www.jimmunol.org/content/192/5/2418.full#ref-list-1](http://www.jimmunol.org/content/192/5/2418.full#ref-list-1)

**Subscription**  Information about subscribing to *The Journal of Immunology* is online at: [http://jimmunol.org/subscription](http://jimmunol.org/subscription)

**Permissions**  Submit copyright permission requests at: [http://www.aai.org/About/Publications/JI/copyright.html](http://www.aai.org/About/Publications/JI/copyright.html)

**Email Alerts**  Receive free email-alerts when new articles cite this article. Sign up at: [http://jimmunol.org/alerts](http://jimmunol.org/alerts)
Galectin-9 Signaling through TIM-3 Is Involved in Neutrophil-Mediated Gram-Negative Bacterial Killing: An Effect Abrogated within the Cystic Fibrosis Lung

Isabel Vega-Carrascal,* David A. Bergin,* Oliver J. McElvaney,* Cormac McCarthy,* Nessa Banville,* Kerstin Pohl,* Mitsuomi Hirashima, ‡ Vijay K. Kuchroo,‡ Emer P. Reeves,*1 and Noel G. McElvaney*1

The T cell Ig and mucin domain-containing molecule (TIM) family of receptors have emerged as potential therapeutic targets to correct abnormal immune function in chronic inflammatory conditions. TIM-3 serves as a functional receptor in structural cells of the airways and via the ligand galectin-9 (Gal-9) can modulate the inflammatory response. The aim of this study was to investigate TIM-3 expression and function in neutrophils, focusing on its potential role in cystic fibrosis (CF) lung disease. Results revealed that TIM-3 mRNA and protein expression values of circulating neutrophils were equal between healthy controls (n = 20) and people with CF (n = 26). TIM-3 was detected on resting neutrophil membranes by FACS analysis, and expression levels significantly increased post IL-8 or TNF-α exposure (p < 0.05). Our data suggest a novel role for TIM-3/Gal-9 signaling involving modulation of cytosolic calcium levels. Via TIM-3 interaction, Gal-9 induced neutrophil degranulation and primed the cell for enhanced NADPH oxidase activity. Killing of Pseudomonas aeruginosa was significantly increased upon bacterial opsonization with Gal-9 (p < 0.05), an effect abrogated by blockade of TIM-3 receptors. This mechanism appeared to be Gram-negative bacteria specific and mediated via Gal-9/LPS binding. Additionally, we have demonstrated that neutrophil TIM-3/Gal-9 signaling is perturbed in the CF airways due to proteolytic degradation of the receptor. In conclusion, results suggest a novel neutrophil defect potentially contributing to the defective bacterial clearance observed in the CF airways and suggest that manipulation of the TIM-3 signaling pathway may be of therapeutic value in CF, preferably in conjunction with antiprotease treatment. The Journal of Immunology, 2014, 192: 2418–2431.

Cystic fibrosis (CF) is the most common lethal genetic disease in whites, affecting at least 60,000 individuals worldwide (1). CF is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) chloride channel (2, 3), and >1500 CFTR mutations leading to defective chloride transport have been identified to date (4, 5). CFTR absence or malfunction causes defective ion transport across the epithelium, a reduction in periciliary liquid volume, and persistent mucus hypersecretion. As a consequence, mucus accumulation on airway surfaces leads to chronic bacterial infection, exacerbated airway inflammation, lung injury, and ultimately death (6). The hallmark of CF lung disease is exacerbated inflammation accompanied by high neutrophil influx, which paradoxically cannot eradicate bacterial infections. As a result, people with CF (PWCF) suffer from chronic bacterial infection and inflammation in the lower airways. Indeed, bronchoalveolar lavage fluid (BALF) of PWCF contains elevated levels of neutrophils and proinflammatory cytokines such as IL-8, IL-6, and TNF-α. The mechanisms linking CFTR dysfunction to chronic bacterial infection and enhanced inflammation in the lung are still not fully understood. The median age at the onset of Pseudomonas colonization is 10 y, and once Pseudomonas aeruginosa colonization occurs, complete bacterial eradication is infrequent (7). Whether neutrophils in CF are intrinsically abnormal or if dysregulated cell activity is a result of chronic inflammation is still a matter of debate (8). However, potential defects in CF neutrophils have been proposed for several of the main neutrophil functions including cell chemotaxis (9), phagocytosis (10), oxidant production, and protease degranulation (11, 12).

T cell Ig and mucin domain–containing molecules (TIMs) are key regulators of immune responses (13–16). TIM proteins are associated with several human inflammatory conditions (15, 17), including rheumatoid arthritis (18), asthma (19), systemic lupus erythematosus (13), multiple sclerosis (20), diabetes (21), and antimicrobial immunity (22). However, the role of TIMs in regulation of the immune response in CF remains underexplored. TIM-3 has been shown to play a role in T cell exhaustion during chronic viral infections and in tumor immunity (23). In line
with its lectin nature, Gal-9 binds to TIM-3 in a carbohydrate-dependent manner, interacting with the N-glycosylated site in the IgV domain. By engagement with Gal-9, TIM-3 has been shown to play a role in apoptosis of Th1 cells (24), and inhibition of Gal-TIM-3 interaction induced an exacerbation of Th1-driven immune response in a mouse model of autoimmune disease (25). Most recently, a repressor of TIM-3 function has been reported, namely HLA-B–associated transcript 3, which protects Th1 cells from Gal-9–mediated cell death (26). Moreover, by use of TIM-3–blocking mAbs, human TIM-3 has been shown to regulate cytotoxic expression at the transcriptional level (27). In line with these results, we have found that physiological relevant levels of Gal-9-induced IL-8 production by CF bronchial epithelial cells, indicating that TIM-3 may initiate the early neutrophil-dominated inflammation in the CF lung. Furthermore, constitutive upregulation of this receptor and its ligand may exacerbate the proinflammatory response of CF bronchial epithelial cells (28, 29).

Peripheral blood neutrophil isolation

Human neutrophils were isolated from heparinized (10 U/ml; Sarstedt, Numbrecht, Germany) venous blood as previously described (32). Cells were resuspended in PBS containing 5 mM glucose (PBSG) unless specified otherwise. The purity of the neutrophil population was confirmed by flow cytometry (as described below) measuring the neutrophil membrane marker CD16b and was found to be >99% (33). Cell viability was systematically monitored before and after each treatment by trypan blue exclusion or by MTT assay and found to be >98%.

Neutrophils were isolated from control volunteers (n = 20; mean age 33.26 ± 1.73 y) who had no underlying medical illnesses and were not receiving any medication. Prior to recruitment, PWCF (n = 26; mean age 22.50 ± 2.7 y, either homozygous or heterozygous for the ΔF508 mutation) were exacerbation free over the preceding 6-wk period. In a subset of PWCF (n = 4) was collected from individuals undergoing bronchoscopy for clinical reasons. Full informed consent was obtained preprocedure according to a protocol approved by Beaumont Hospital Ethics Review Board. Bronchoscopy was performed with the bronchoscope directed to the lingula and right middle lobe. BALF was performed by instilling 1 ml/kg sterile normal saline per lobe. All BALF samples were centrifuged at 1000 × g for 10 min at 4°C, and cell-free supernatants were aliquoted and stored at −80°C for subsequent analysis.

Materials and Methods

Reagents

Unless stated otherwise, chemical reagents were purchased from Sigma-Aldrich (Dublin, Ireland) and were of the highest purity available.

BALF sample collection

BALF from adult PWCF (n = 4) was collected from individuals undergoing bronchoscopy for clinical reasons. Full informed consent was obtained preprocedure according to a protocol approved by Beaumont Hospital Ethics Committee. Bronchoscopy was performed with the bronchoscope directed to the lingula and right middle lobe. BALF was performed by instilling 1 ml/kg sterile normal saline per lobe. All BALF samples were centrifuged at 1000 × g for 10 min at 4°C, and cell-free supernatants were aliquoted and stored at −80°C for subsequent analysis.

Flow cytometry experiments

Flow cytometry was carried out to evaluate the membrane expression of CD16b as a measure of cell purity (35). Neutrophils were then fixed (5% (w/v) paraformaldehyde (PFA) and blocked (2% (w/v) BSA) for 30 min at room temperature. After washing (PBS ×2), neutrophils (1 × 10⁷) were incubated with 1 μg/10⁶ mouse monoclonal anti-CD16b (Santa Cruz Bio-technology). Control samples were exposed to relevant nonspecific isotype control IgG or secondary-labeled Ab alone (FITC-labeled bovine anti-mouse). For TIM-3 expression studies, human or mouse purified neutrophils were incubated with 1 μg/ml of rat monoclonal anti-TIM-3 Ab or PE–anti-mouse TIM-3 Ab (rat monoclonal, 1 μg/ml; R&D Systems, Abingdon, U.K.), hCAP-18 (rabbit polyclonal, 1 μg/ml; Invitrogen, Lund, Sweden), matrix metalloproteinase-9 (MMP-9; goat polyclonal, 1 μg/ml; R&D Systems), and myeloperoxidase (MPO; goat polyclonal, 1 μg/ml; R&D Systems). In a subset of experiments, rabbit polyclonal anti-human TIM-3 Ab (1 μg/ml) was used that was purchased from MBL International (Woburn, MA). Mouse monoclonal anti-p-tyrosine (clone 4G10 Ab; 1 μg/ml) was purchased from Millipore. The secondary Abs were HRP-linked anti-rabbit, anti-mouse, or anti-goat IgG (Cell Signaling Technology, Danvers, MA). Blots were developed with Immobilon Western chemiluminescent HRP substrate (Millipore) and visualized on the Syngene G:Box chemi XL gel documentation system (Synoptics, Cambridge, U.K.) or by exposing the membrane to Kodak X-Ormat LS film (Kodak).

Quantitative real-time PCR

Total RNA was extracted from neutrophils (1 × 10⁶) using TRI reagent following the manufacturer’s instructions. cDNA (2 μl) was amplified with SYBR green I Master mix (Roche, Basel, Switzerland) using the LightCycler system (Roche Diagnostics). PCR was performed as previously described (35) using TIM-3 primer sets (amplicon size 96 bp) as follows: forward primer 5′-TCC AAG GAT GCT TAC CAG CAG-3′ and reverse primer 5′-GCC AAT GTG ATT GTG AGA TT-3′. All samples were carried out in duplicate 20-μl reactions in 96-well plates, and a negative control with no cDNA template was included in every run. Specificity of the amplicon products was confirmed by visual inspection of melting curves. The relative expression of the gene was determined using the 2−ΔΔct cycle method (36) with GAPDH as an internal control. The primer set for GAPDH (amplicon size 113 bp) was as follows: forward primer 5′-CAT GAG AAT TAG AAT AAC AGC CT-3′ and reverse primer 5′-AGT CCT TCC AGC ATTA CCA AAG T-3′.

SDS-PAGE and Western blotting

For preparation of neutrophil whole cell lysates for SDS-PAGE analysis, 1 × 10⁷ cells was precipitated with 10% TCA on ice. Electrophoresis of samples was conducted according to Laemmli’s method (37). Denatured protein samples (20 μl) were resolved on 10 or 12.5% (w/v) resolving gel and 4% (w/v) stacking gel. SeeBlue Plus2 Prestained molecular mass markers (4 μl; Invitrogen) were loaded on each gel for determination of molecular weight. Gels were run in an ATTO AE6450 electrophoresis tank (ATTO Corporation, Tokyo, Japan), and electrophoresis was carried out for 60–90 min at 120 V.

Following electrophoresis, proteins were transferred onto nitrocellulose membrane at 150 mA for 60 min using a semidry blotting apparatus. Following transfer, membranes were blocked with 5% (w/v) nonfat powdered milk in PBS containing 0.1% (v/v) Tween-20 for 1 h at room temperature. For immunolabeling of the desired proteins, blots were incubated overnight at 4°C in blocking buffer containing Ab against TIM-3 (goat polyclonal, 1 μg/ml; R&D Systems, Abingdon, U.K.), hCAP-18 (rabbit polyclonal, 1 μg/ml; Invitrogen, Lund, Sweden), matrix metalloproteinase-9 (MMP-9; goat polyclonal, 1 μg/ml; R&D Systems), and myeloperoxidase (MPO; goat polyclonal, 1 μg/ml; R&D Systems). In a subset of experiments, rabbit polyclonal anti-human TIM-3 Ab (1 μg/ml) was used that was purchased from MBL International (Woburn, MA). Mouse monoclonal anti-p-tyrosine (clone 4G10 Ab; 1 μg/ml) was purchased from Millipore. The secondary Abs were HRP-linked anti-rabbit, anti-mouse, or anti-goat IgG (Cell Signaling Technology, Danvers, MA). Blots were developed with Immobilon Western chemiluminescent HRP substrate (Millipore) and visualized on the Syngene G:Box chemi XL gel documentation system (Synoptics, Cambridge, U.K.) or by exposing the membrane to Kodak X-Ormat LS film (Kodak).
intensity (MFI) for each experiment was determined using BD CellQuest Pro software (BD Biosciences).

TIM-3 immunoprecipitation
TIM-3 immunoprecipitation was performed exactly as previously described (35). Neutrophils (1 × 10⁷) were resuspended in 1 ml Lambechts Break Buffer (10 mM KCl, 3 mM NaCl, 4 mM MgCl₂, and 10 mM PIPES [pH 7.2]) supplemented with protease inhibitors Complete Mini tablets and phosphatase inhibitors PhosphoStop Mini tablets (Roche, Basel, Switzerland) at 4°C. Cell membranes were purified by ultracentrifugation as previously described (35) and the membrane pellet resuspended in 1 ml radioimmunoprecipitation assay buffer (150 mM NaCl, 50 mM Tris-HCl [pH 8], 0.5% [w/v] sodium deoxycholate, 1% Triton X-100 [v/v], and 0.1% [v/v] SDS) containing protease and phosphatase inhibitors. Samples were precleared with 6 μg normal goat IgG (Santa Cruz Biotechnology) and 50 μg protein-G Dynabeads (Invitrogen) for 1 h at 4°C with rotation. The precleared samples were incubated with 6 μg goat anti-TIM-3 Ab for 2 h at 4°C with rotation, and the immunocomplex was captured by incubation with 50 μg protein-G Dynabeads as previously described (35). The activation of TIM-3 by Gal-9 was analyzed by Western blot of immunoprecipitated cell membranes probed for p-tyrosine. Blots were stripped with 0.1% [w/v] SDS) containing protease and phosphatase inhibitors. Samples were resuspended at 2.5 × 10⁶ cells/ml in assay buffer and left untreated or incubated with 30 mM lactose or 30 mM sucrose for 30 min at 37°C and 5% CO₂. A total of 100 μl neutrophil suspension (1.25 × 10⁵ cells) was pipetted into a black 96-well plate in duplicate, and fluorescence was recorded at room temperature every 5 s in a Victor X3 2030 Multilabel reader (PerkinElmer) using excitation and emission wavelengths of 485 and 535 nm, respectively. After 60–90 s, Gal-9 was added (final assay concentrations of 0, 50, 100, and 500 nM), and intracellular Ca²⁺ fluorescence was monitored for up to 10 min. Protocolically stable human Gal-9 was a kind gift from GalPharma (Kagawa, Japan). Expression and purification of stable human Gal-9 was as previously described (18).

Neutrophil superoxide production
Neutrophil superoxide (O₂⁻) generation was measured by the cytochrome c reduction assay as previously described (39). Neutrophils were resuspended in sterile polypropylene tubes (Sarstedt) at 2.5 × 10⁶ cells/ml in assay buffer and left untreated or incubated with 30 mM lactose or 30 mM sucrose for 30 min at 37°C and 5% CO₂. A total of 100 μl neutrophil suspension (1.25 × 10⁵ cells) was pipetted into a black 96-well plate in duplicate, and fluorescence was recorded at room temperature every 5 s in a Victor X3 2030 Multilabel reader (PerkinElmer) using excitation and emission wavelengths of 485 and 535 nm, respectively. After 60–90 s, Gal-9 was added (final assay concentrations of 0, 50, 100, and 500 nM), and intracellular Ca²⁺ fluorescence was monitored for up to 10 min. Protocolically stable human Gal-9 was a kind gift from GalPharma (Kagawa, Japan). Expression and purification of stable human Gal-9 was as previously described (18).

Neutrophil degranulation assays
Neutrophils (5 × 10⁶/ml) suspended in PBSG remained untreated or were incubated with Gal-9 (0, 50, and 500 nM) or MFLM (1 μM) and cytochalasin B (Cyto-B; 5 μM), and cell aliquots were taken at 0, 15, or 30 min. Cell-free supernatants were harvested following centrifugation at 500 × g for 5 min at 4°C and analyzed for degranulated proteins: MPO as a marker of primary granule release, hCAP-18 as a marker of secondary granule release, and MMP-9 as a marker of tertiary granule release by Western blotting. Degranulation of neutrophil elastase to the outside of the cell was quantified by performing an NE activity assay using the NE-specific substrate N-methoxy succinyl-ala-alav-pro-val-p-nitroanilide, as previously described (40). Samples (10 μl) were mixed with 90 μl 3 mM substrate in assay buffer (0.5 mM NaCl, 0.1% [v/v] Brij-35, and 0.1 M HEPES [pH 7.5]). OD was recorded at 405 nm for 5 min at 1-min intervals at 37°C using a Wallac 1420 Victor2 multilabel counter (Wallac).

Determination of bactericidal activity
P. aeruginosa strain PAO1 and Staphylococcus aureus strain (8325-4) were used in this study. Bacteria were stored at −80°C as glycerol stocks (50% [v/v] glycerol in tryptic soy broth) and streaked onto tryptic soy agar plates to obtain single colonies after an overnight incubation at 37°C. A single colony was then suspended in BBL tryptic soy broth (BD Biosciences) and cultured at 37°C and 200 rpm in a shaker incubator (New Brunswick Scientific, Eppendorf, Cambridge, U.K.). Bacterial quantification was achieved by measuring absorbance at 600 nm using a Bio photometer (Eppendorf) according to the following conversion values: P. aeruginosa PAO1, OD₅₆₀ of 0.185 = 1 × 10⁸ bacteria/ml and S. aureus strain (8325-4), OD₅₆₀ of 0.170 = 1 × 10⁹ bacteria/ml. The role of TIM-3 and Gal-9 in bacterial killing was assessed in vitro following a previously described method (32) using a neutrophil/bacteria ratio of 1:1. In brief, bacteria (5 × 10⁷) were pelleted by centrifugation at 20,000 × g for 10 min at room temperature, resuspended in 500 μl 50% (v/v) autologous plasma in PBS, and opsonized for 30 min at 37°C. In a subset of experiments, Gal-9 in PBS (0, 50, 100, or 500 nM) was used as an agonist. Freshly isolated neutrophils were resuspended in a total volume of 500 μl PBSG, in the presence or absence of TIM-3–Fc fusion protein (rTIM-3–Fc; 5 μg/ml) or control fusion protein (rhG1F1c; 5 μg/ml). rTIM-3–Fc and human IgG1–Fc (110-HG) were both purchased from R&D Systems. Opsonized bacteria (1 × 10⁷/100 μl) were added to neutrophils in a rapidly stirring oxygenated chamber, and 100-μl aliquots were removed at 2, 4, and 8 min. Serial to quench extracellular and membrane-adherent FITC-labeled bacteria. Tryp1 trytic soy agar plates and incubated at 37°C. Viable bacterial CFUs were counted the following day. Bacterial viability was expressed as a percentage of bacterial counts at time 0 min, the latter representing 100% viability. In a subset of experiments to determine if TIM-3 was involved in Gal-9–mediated bacterial killing, neutrophils were preincubated with TIM-3–blocking Ab (mouse monoclonal derived from a hybridoma [clone 1G5]). 10 μg/ml or mouse IgG control (Santa Cruz Biotechnology) for 10 min at room temperature prior to the addition of bacteria.

Neutrophil phagocytosis assays
Phagocytosis assays were carried out as previously described with some modifications (41). In brief, P. aeruginosa (2 × 10⁷ bacteria) were resuspended in 1 ml labeling buffer (50 mM Na₂CO₃ and 100 mM NaCl [pH 9]) containing 0.5 mg/ml FITC and incubated for 20 min at room temperature, pelleted by brief centrifugation, and resuspended in 1 ml PBS containing 500 μl PBSG. Bacteria were either untreated or opsonized with Gal-9 (50 nM) for 30 min and then washed with PBS. For analyzing neutrophil phagocytosis, FITC-labeled bacteria (5 × 10⁸ of either Gal-9 opsonized or unopsonized) and neutrophils were mixed at 37°C in a rapidly stirring oxygenated chamber at a 10:1 ratio. Aliquots were removed at 0 and 5 min and placed in 0.4% (v/v) trypsin in PBS to quench extracellular and membrane-adherent FITC-labeled bacteria. Cells were then analyzed by flow cytometry for phagocytosed fluorescent bacteria as previously described (41).

Gal-9/LPS binding assays
Interaction between P. aeruginosa LPS and Gal-9 was determined by an in-house developed solid-phase binding assay based on previously published Gal-3/LPS binding studies (42–44). High-binding, Immunoll 2HB flat-bottom polystyrene microtiter plates (Thermo Scientific, Dublin, Ireland) were coated overnight at 4°C with 100 μg/ml commercial LPS purified from P. aeruginosa, serotype 10 (50 μg/ml in Volumes buffer). Following three washes with PBS containing 1% (v/v) Tween-20, 100 μl PBS containing Gal-9 (0–500 nM) was added to each well and incubated for 2 h at 37°C. The plates were then washed (five times), incubated for 2 h with 100 μl 10 μg/ml Gal-9 Ab (clone F9-M; Galpharma) in PBS, washed, and then incubated for 1 h with anti-mouse–HRP Ab (1:1000 in PBS). After a final wash, plates were incubated for 1 h with ARBS, and Gal-9/LPS binding was confirmed by measuring absorbance at 405 nm. Controls included uncoated PBS wells, wells without Gal-9, and wells treated with Ab only.

Gal-9 binding to bacteria was also measured by flow cytometry. P. aeruginosa and S. aureus (5 × 10⁷) were pelleted by centrifugation, fixed in 3.7% (w/v) paraformaldehyde in PBS for 15 min at room temperature, washed in 1 ml PBS (three times), and resuspended in 1 ml PBS. Bacteria (1 × 10⁷) were incubated for 1 h at 4°C with end-to-end rotation in 500 μl PBS containing 500 nM Gal-9 or PBS alone. Following centrifugation, bacteria were washed in PBS (three times) and incubated with 20 μl PE-labeled Gal-9 Ab or PE-labeled mouse IgG control for 30 min at room temperature in the dark. After a final wash, the bacteria were resuspended in PBS and Gal-9 binding assessed by flow cytometry.

Statistical analysis
Data were analyzed with GraphPad Prism 4.0 software package (GraphPad Software, San Diego, CA). Results of cytochrome c assays, intracellular
Ca\textsuperscript{2+} measurements, and killing assays were analyzed by two-way ANOVA. For data sets less than \( n = 6 \), the Student \( t \) test was employed (45). Data are expressed as mean \( \pm \) SE of at least three independent experiments performed in triplicate unless otherwise stated. Results were considered significant (*') when \( p < 0.05 \).

Results

TIM-3 is equally expressed by circulating healthy control and CF neutrophils

Altered TIM-3 expression in peripheral monocyctic cells has been reported associated with a number of respiratory diseases (46); however, whether TIM-3 is expressed by human neutrophils and how TIM-3 expression is affected by CF are not known. To address this, we employed purified peripheral blood neutrophils from healthy controls and PWCF, whom were either homozygous or heterozygous for the \( \Delta F 5 0 8 \) mutation, and examined TIM-3 expression by quantitative real-time PCR. TIM-3 was found to be present in all cell types, with a slight decrease in TIM-3 mRNA expression in neutrophils from PWCF homozygous for the \( \Delta F 5 0 8 \) mutation, although this did not reach statistical significance (Fig. 1A).

Next, we investigated TIM-3 expression at the protein level by flow cytometry analysis. All neutrophils were fixed in paraformaldehyde prior to incubation with TIM-3 Ab. TIM-3 expression was detected on the membranes of peripheral blood neutrophils from PWCF and healthy controls, and there was no significant difference in the number of TIM-3–positive cells (Fig. 1B). This result is in contrast to our previous observation of increased TIM-3 on CF bronchial epithelial cells (35), and therefore, to consolidate this result, the expression of TIM-3 was examined in whole-cell lysates obtained by TCA precipitation. Western blot analysis of whole neutrophil lysates identified two characteristic bands for TIM-3 of 64 and 36 kDa (Fig. 1C). In line with previous reports on the molecular mass of TIM-3 (35, 47), the fully glycosylated form of TIM-3 (64 kDa) and also a second band indicative of nonglycosylated TIM-3 (36 kDa) (Fig. 1C). Moreover, to evaluate potential differential expression of TIM-3 protein by circulating neutrophils from PWCF compared with healthy controls, cell lysates were obtained by TCA precipitation of neutrophils from healthy and \( \Delta F 5 0 8 \) homozygous PWCF. Expression of mature TIM-3 (64 kDa) was analyzed by densitometry of immunoblots, and in line with results demonstrating equal mRNA expression, no significant difference in TIM-3 protein expression was detected (Fig. 1D).

TIM-3 membrane expression is increased post–proinflammatory challenge

As expression of TIM-3 on circulating human neutrophil membranes was established (Fig. 1B), additional studies were conducted to determine whether inflammatory stimuli could further influence TIM-3 expression of purified cells. Neutrophils were treated with IL-8 (10 ng/ml) or TNF-\( \alpha \) (10 ng/ml), and TIM-3 expression was measured by flow cytometry after 5 and 10 min treatment, respectively. The MFI of TIM-3 on peripheral unstimulated neutrophils was 4.8 \( \pm \) 0.16 (Fig. 2A, 2B), and the percentage of TIM-3–positive cells following stimulation with IL-8 or TNF-\( \alpha \) was 28.47 \( \pm \) 2.22 and 29.98 \( \pm \) 1.20, respectively (Fig. 2C). These data revealed that inflammatory stimuli can modulate TIM-3 membrane levels and that IL-8 (\( p < 0.05 \)) and TNF-\( \alpha \) (\( p < 0.05 \)) induced a significant increase in the percentage of TIM-3–positive neutrophils (Fig. 2C).

Subsequent experiments considered whether TIM-3 was expressed post–neutrophil migration by employing the thioglycollate-induced sterile peritonitis model. Female BALB/c mice were injected i.p. with sterile thioglycollate for 6 h, following which neutrophils were recovered from the peritoneal cavity. As illustrated in Fig. 2D, elicited neutrophils retained TIM-3 surface expression. This result suggests that TIM-3 would be expressed on neutrophils post–migration to the site of inflammation/infection and be capable of exerting a putative function following translocation from the systemic circulation.
We next investigated if TIM-3 expressed on neutrophils was a functional receptor for Gal-9. For this purpose, neutrophils were treated with Gal-9, which has previously been shown to activate TIM-3 by phosphorylation of the cytosolic tyrosine motif Y265 (47). After 15 min stimulation with Gal-9 (50 nM), TIM-3 was immunoprecipitated from neutrophil cell extracts with goat anti–TIM-3 Ab, and normal goat IgG was used as a control for nonspecific binding. Western blot analysis of immunoprecipitated TIM-3 (Fig. 2F) shows that TIM-3 in treated cells and was also present on the surface of transmigrating neutrophils, we next set out to investigate whether TIM-3 played a role in neutrophil antimicrobial function. The degranulation of proteolytic enzymes and peptides is required for the bactericidal activity of neutrophils. For this reason, we evaluated the kinetics of degranulation upon cell challenge with the TIM-3 ligand Gal-9. Upon exposure, Gal-9–induced (50 or 500 nM) release of granule proteins was quantified in the extracellular supernatant by immunoblotting. Levels of cell released MPO from primary granules (Fig. 3A), hCAP-18 from secondary granules (Fig. 3B), and MMP-9 from tertiary granules (Fig. 3C) were significantly higher than healthy controls (p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Gal-9 induces neutrophil degranulation via TIM-3 interaction

As TIM-3 was found on membranes of resting and IL-8– or TNF-α–challenged cells and was also present on the surface of transmigrating neutrophils, we next set out to investigate whether TIM-3 played a role in neutrophil antimicrobial function. The degranulation of proteolytic enzymes and peptides is required for the bactericidal activity of neutrophils. For this reason, we evaluated the kinetics of degranulation upon cell challenge with the TIM-3 ligand Gal-9. Upon exposure, Gal-9–induced (50 or 500 nM) release of granule proteins was quantified in the extracellular supernatant by immunoblotting. Levels of cell released MPO from primary granules (Fig. 3A), hCAP-18 from secondary granules (Fig. 3B), and MMP-9 from tertiary granules (Fig. 3C) were significantly increased in the presence of Gal-9 (50 or 500 nM) post–15- or 30-min exposure (p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05) and an increased release by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05) and an increased release by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

We next investigated if TIM-3 expressed on neutrophils was a functional receptor for Gal-9. For this purpose, neutrophils were treated with Gal-9, which has previously been shown to activate TIM-3 by phosphorylation of the cytosolic tyrosine motif Y265 (47). After 15 min stimulation with Gal-9 (50 nM), TIM-3 was immunoprecipitated from neutrophil cell extracts with goat anti–TIM-3 Ab, and normal goat IgG was used as a control for nonspecific binding. Western blot analysis of immunoprecipitated TIM-3 (Fig. 2F) shows that TIM-3 in treated cells and was also present on the surface of transmigrating neutrophils, we next set out to investigate whether TIM-3 played a role in neutrophil antimicrobial function. The degranulation of proteolytic enzymes and peptides is required for the bactericidal activity of neutrophils. For this reason, we evaluated the kinetics of degranulation upon cell challenge with the TIM-3 ligand Gal-9. Upon exposure, Gal-9–induced (50 or 500 nM) release of granule proteins was quantified in the extracellular supernatant by immunoblotting. Levels of cell released MPO from primary granules (Fig. 3A), hCAP-18 from secondary granules (Fig. 3B), and MMP-9 from tertiary granules (Fig. 3C) were significantly increased in the presence of Gal-9 (50 or 500 nM) post–15- or 30-min exposure (p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.

Post–15-min exposure to 50 nM Gal-9, there was a significant increase in the release of NE by CF neutrophils, although this did not reach significance (5.57 ± 0.64 to 7.49 ± 0.48 nM; p < 0.05). Ensuing experiments were designed to investigate Gal-9–induced degranulation of NE and compare the difference between CF and healthy control cells.
was made between the responses induced by Gal-9 (50 nM) and that of fMLF (1 μM) in combination with Cyto-B (5 μM). Post-activation for 15 min, a strong MPO immunoband indicative of primary granule release was observed in both Gal-9 and fMLF/Cyto-B–challenged cells (Fig. 3E).

Subsequent experiments were performed to confirm that Gal-9–evoked neutrophil degranulation was TIM-3 receptor mediated. Neutrophils were incubated with a human TIM-3–blocking Ab or relevant IgG control for 10 min in the presence or absence of 10 μg/ml TIM-3–blocking Ab or mouse IgG1Fc control Ab (IgG Con) followed by Gal-9 (500 nM), and aliquots were taken after 30 min. Cell supernatants were analyzed for MPO, hCAP-18, or MMP-9. Results shown are mean ± SE of n = 3 independent experiments. *p < 0.05, **p < 0.01 compared with Gal-9 treatment by Student t test.

The TIM-3/Gal-9 signaling axis confers a novel neutrophil-priming mechanism

Intravascular killing in neutrophils occurs not only due to release of proteolytic enzymes, but also requires NADPH oxidase activity, which results in O$_2^-$ generation. Prompted by the data indicating a role for Gal-9 and TIM-3 as a novel signaling mechanism leading to degranulation, ensuing experiments focused on the impact of Gal-9/TIM-3 signaling on NADPH oxidase activation. Neutrophils were challenged with increasing concentrations of Gal-9 (50, 100, 250, or 500 nM), and O$_2^-$ generation was monitored.
As Gal-3 has previously been shown to prime neutrophils for O$_2^-$ production (49), we next tested if Gal-9 could also act as a priming agent. Neutrophils were treated for 10 min with increasing levels of Gal-9 (0, 50, 100, 250, and 500 nM), fMLF (1 μM final concentration) was then added, and cytochrome c reduction as a measure of O$_2^-$ production was monitored for 25 min (Fig. 4B). In line with previous reports, fMLF alone is a poor inducer of O$_2^-$ production (33). However, treatment of cells with Gal-9 enhanced NADPH oxidase activity in a dose-dependent manner. Of note, the 50 nM dose of Gal-9, which did not trigger O$_2^-$ production alone (Fig. 4A), induced a marked release of O$_2^-$ following fMLF treatment, indicating that Gal-9 can act as a neutrophil-priming agent.

An increase in intracellular cytosolic Ca$^{2+}$ is a feature of neutrophil priming and activation (50). Moreover, Gal-9 has been shown to promote intracellular Ca$^{2+}$ mobilization via TIM-3 in mouse Th1 cells (24) and a number of human cell lines including HL-60 cells (51). To determine whether Gal-9 can trigger a Ca$^{2+}$ flux in neutrophils, intracellular Ca$^{2+}$ mobilization was monitored following stimulation with 50, 100, or 500 nM Gal-9 (Fig. 5A). A rapid increase in cytoplasmic Ca$^{2+}$ was observed immediately after addition of Gal-9, reaching a maximum after ~20 s without returning to basal levels. All Gal-9 treatments triggered intracellular Ca$^{2+}$ mobilization, but most significantly by use of 100 or 500 nM Gal-9 (p < 0.05) (Fig. 5B). To confirm that this effect was caused by Gal-9 binding to β-galactoside in the TIM-3 receptor, neutrophils were preincubated with lactose (30 mM), which has been shown to prevent Gal-9 binding to TIM-3 (52), or sucrose (30 mM) as a negative control. Cotreatment with lactose significantly decreased Gal-9–evoked intracellular Ca$^{2+}$ flux, whereas control sucrose treatment did not reverse the effects of Gal-9 (Fig. 5C, 5D).

Collectively, results demonstrate TIM-3 expression on resting and IL-8– or TNF-α–primed neutrophil cell surfaces. Gal-9 was shown to stimulate signal transduction in the neutrophil, leading to intracellular Ca$^{2+}$ mobilization, neutrophil degranulation, and NADPH oxidase activity via TIM-3 interactions. Taken together, this study has identified a novel role for TIM-3/Gal-9 in neutrophil function with potentially important consequences in neutrophil antimicrobial activity.

**TIM-3/Gal-9 signaling plays an essential role in opsonization and phagocytosis of P. aeruginosa**

A direct role in bacterial killing has recently been revealed for TIM-3/Gal-9 host resistance to *Mycobacterium tuberculosis* (22). Moreover, a recent study has shown that killing of *Escherichia coli* by monocytc cells was TIM-3 dependent, as phagocytosis and killing mechanisms were inhibited in the presence of soluble TIM-3 (53). Within this study, we investigated whether Gal-9 plays a role in neutrophil-mediated bacterial killing via TIM-3 interaction. As Gal-9 is found in human serum of healthy individuals (54, 55), bacterial opsonization with serum was performed, and killing assays were carried out in the presence or absence of rhTIM-3–Fc fusion protein (5 μg/ml). As shown in Fig. 6A, the presence of rhTIM-3–Fc protein significantly (p < 0.05) increased survival of serum-opsonized *P. aeruginosa* compared with controls at the earlier time points of 2 min (44 versus 22% survival) and 4 min (22 versus 7% survival). This result is in agreement with the previous study in human immune cells that demonstrated that blocking TIM-3 interaction with serum-opsonized bacteria resulted in decreased bacterial killing (53). In contrast, rhTIM-3–Fc treatment did not significantly alter *S. aureus* neutrophil-mediated killing (Fig. 6B). These results suggest that TIM-3 expression on neutrophils is directly involved in a killing mechanism specific for *P. aeruginosa*, but not present in *S. aureus*.

The previous experiment has demonstrated that TIM-3 on neutrophils is involved in bacterial killing. However, there are no known bacterial components that can directly bind to TIM-3. Thus, it is likely that the interaction blocked by soluble rhTIM-3 is TIM-3/Gal-9, because Gal-9 is the only known ligand for TIM-3. Indeed, Gal-9 has been reported to bind to *Leishmania major* through specific interaction with poly-β-galactosyl epitopes, and Gal-3 has also been found to bind to glycans expressed on the
surface of parasites such as *L. major* (56) and fungi such as *Candida albicans* (57). Thus, galectins present in serum can potentially act as pathogen recognition molecules against a varied range of microorganisms. Within this study we assessed whether Gal-9 was capable of binding to LPS from *P. aeruginosa* by a modified solid-binding ELISA. Commercially available LPS purified from *P. aeruginosa* (50 μg/well) was employed to coat a 96-well plate, and wells were incubated overnight with increasing levels of Gal-9 (0–500 nM). Binding was determined by using a Gal-9–specific Ab, and a positive response could only be obtained if direct interaction between LPS and Gal-9 occurred. Fig. 7A shows that Gal-9 binds to *P. aeruginosa* LPS and that maximal binding was obtained between 50 and 100 nM Gal-9. Once Gal-9 was shown capable of binding *P. aeruginosa*–derived LPS, we next investigated whether Gal-9 could directly bind to bacteria. To this end, both *S. aureus* and *P. aeruginosa* cells were fixed with paraformaldehyde and incubated overnight with Gal-9 (50 nM). Importantly, Gal-9 did not bind to *S. aureus* (Fig. 7B, 7D), but in contrast, Gal-9 was detected on the surface of *P. aeruginosa* bacteria (Fig. 7C, 7D). Subsequent experiments were designed to investigate whether Gal-9 opsonization of *P. aeruginosa*–enhanced phagocytosis of bacteria. For analyzing neutrophil phagocytosis, FITC-labeled bacteria (5 × 10^7 of either Gal-9 opsonized or unopsonized) and neutrophils were mixed at 37˚C at a 10:1 ratio. The fluorescence of bacteria that were either unphagocytosed or adhered to the outer membrane of the cell was quenched by trypan blue prior to analyses by flow cytometry. Results revealed a significant 4-fold increase in the level of phagocytosed Gal-9–opsonized bacteria compared with unopsonized (*p* < 0.0001) (Fig. 7E). Thus, Gal-9 was revealed as a novel pathogen recognition molecule, specific for Gram-negative bacteria, and in particular *P. aeruginosa*.

**Gal-9 opsonization of *P. aeruginosa* induces neutrophil TIM-3–mediated bacterial killing, an antimicrobial mechanism potentially perturbed in the CF airways**

Having established that Gal-9 can bind to Gram-negative bacteria via interaction with LPS on *P. aeruginosa*, we next investigated whether Gal-9 opsonization would be sufficient to induce bacterial killing by neutrophils. To this end, *P. aeruginosa* bacteria were opsonized with Gal-9 instead of serum and then employed in a neutrophil-killing assay. As shown in Fig. 8A, opsonization with 50 nM Gal-9 was sufficient to induce on average 28% more killing after 2 min compared with nonopsonized bacteria (*p* < 0.05). This enhanced killing promoted by opsonization with Gal-9 was sustained after 16-min incubation with an average increase in *P. aeruginosa* killing of 46% observed (*p* < 0.05). Conversely, blockade of TIM-3 by use of a TIM-3–blocking Ab abrogated the promotion of Gal-9–opsonized (50 nM) *P. aeruginosa* killing. This effect was not observed when neutrophils were pretreated with a relevant mouse IgG control. Moreover, increasing the dose of Gal-9 during the opsonization process to 100 or 500 nM did not increase bacterial killing (result not shown).

Of major relevance to bacterial killing in CF, a previous study reported defective neutrophil intraphagosomal killing of *P. aeruginosa*. Thus, it was important to extend our experiments to compare the effect of Gal-9 on the level of bacterial killing by healthy control and CF neutrophils (Fig. 8B). By using unopsonized bacteria, the pattern of in vitro killing was in agreement with previous reports describing increased killing of *P. aeruginosa* by control cells com-

![Image](http://www.jimmunol.org/)
pared with CF neutrophils (bacterial survival 73.66 ± 1.39 and 91.64 ± 6.82 for healthy control and CF cells after 16 min incubation, respectively; \( p < 0.05 \)). Opsonization of bacteria with Gal-9 (50 nM) increased killing by ~14 and 38% by control and CF cells, respectively, with no significant difference in the level of killing observed between the two cell types after 16-min incubation (bacterial survival 59.52 ± 1.9 and 53.5 ± 4.1 for healthy control and CF cells, respectively). In addition, the observed increased bactericidal activity prompted us to evaluate whether Gal-9 itself exhibited bactericidal or bacteriostatic properties. Our results showed that Gal-9 at physiological (50 nM) or a high dose (500 nM) did not display bactericidal properties against \( P. aeruginosa \), indicating that Gal-9 was not directly involved in bacterial killing, and the bactericidal properties required the involvement of phagocytes (Fig. 8C).

We have previously shown that TIM-3 and Gal-9 are completely absent in the adult CF lung due to proteolytic degradation by neutrophil-derived proteases (NE and proteinase 3) (35). The lack of bacterial killing via the TIM-3/Gal-9 mechanism may have a negative impact on the eradication of Gram-negative bacterial infections, which may in part explain chronic colonization by \( P. aeruginosa \) of the CF lower airways. Therefore, we next evaluated the fate of neutrophil-associated TIM-3 under conditions prevailing in the CF airways. For this experiment, circulating and BALF neutrophils were isolated from PWCF (\( n = 3 \)). TIM-3 expression was detected on membranes of peripheral blood neutrophils from PWCF, and the expression was significantly increased postexposure to IL-8 (\( p < 0.05 \)) (Fig. 8D). The MFI of TIM-3 on peripheral neutrophils from PWCF was 4.8 ± 0.16 and following stimulation with IL-8 was 11.45 ± 2.56 (Fig. 8E). In contrast, negligible levels of TIM-3 were detected on neutrophils isolated from CF BALF (Fig. 8D, 8E). To understand whether the lack of TIM-3 on CF BALF neutrophils was due to proteolytic degradation by neutrophil-derived proteases, healthy control neutrophils were treated with CF BALF (200 μg) or 100 nM NE for 1 or 2 h, respectively, at 37°C in PBS. The remaining levels of TIM-3 on the cell outer surface were measured by flow cytometry. Both CF BALF and NE significantly decreased the level of TIM-3 cell outer surface expression (\( p < 0.01 \) and \( p < 0.05 \), respectively) (Fig. 8F). These results confirm the ability of neutrophil-derived serine proteases to degrade native neutrophil TIM-3 in vivo.

Collectively, the results of this study demonstrate that TIM-3 expressed on neutrophils plays a direct role in bacterial killing. Opsonization of \( P. aeruginosa \) with a physiologically relevant dose of Gal-9 promoted significant bacterial killing that could be reversed by blockade of neutrophil TIM-3 receptors. This previously unidentified mechanism for neutrophil killing of \( P. aeruginosa \) is likely to be disrupted in the CF lung due to protease action with important consequences for bacterial clearance.

**Discussion**

TIM-3 was initially described as a marker of Th1 cells (25), and since then, it has been shown to be expressed in a variety of immune cells including Th17 (27), dendritic cells (58), NK cells (59), NKT cells (20), monocytes (20), macrophages (53, 60), and mast cells (61). A study also examined whether TIM-3 was inhibited by blockade of neutrophil TIM-3 receptors. This previously unidentified mechanism for neutrophil killing of \( P. aeruginosa \) is likely to be disrupted in the CF lung due to protease action with important consequences for bacterial clearance.

Our data demonstrate TIM-3 expression in resting neutrophils by Western blot analysis of whole neutrophil protein obtained by TCA precipitation. This technique preserves neutrophil proteins and protects them from rapid proteolytic degradation (65). These results were further confirmed by flow cytometric analysis of resting neutrophils or cells exposed to proinflammatory stimuli, which indicated that TIM-3 is present on the neutrophil mem-
brane. In line with studies indicating intracellular storage of receptors, with prompt upregulation on the neutrophil surface upon exposure to inflammatory stimuli (66), results revealed upregulation of TIM-3 in response to both IL-8 and TNF-α. However, in contrast with the observed upregulation of TIM-3 in CF bronchial epithelial cells (35), CF circulating neutrophils did not show significantly altered expression compared with healthy control cells, supporting the notion of differential TIM-3 expression depending on cell type and activation stage. Moreover, surface expression of neutrophil receptors change following recruitment to sites of inflammation. For example, C5a receptor CD11b and FcγRII have been shown to be upregulated in human extravasated neutrophils, whereas 1-selectin was downregulated on the surface of recruited cells (67). Therefore, to assess whether TIM-3 would still be present on neutrophils recruited to a site of infection/inflammation, TIM-3 expression was examined in extravasated peritoneal neutrophils obtained after thioglycollate injection. TIM-3 surface expression was confirmed in this context, suggesting that TIM-3 is likely present on the surface of transmigrating cells, thus supporting previous studies (30). Moreover, Gal-9 has been shown to induce tyrosine phosphorylation in several cell types (47, 58) and in this study, TIM-3 phosphorylation upon Gal-9 stimulation was demonstrated in neutrophils, indicating the presence of a functional TIM-3 receptor. This observation is of importance, as it suggests that epithelial TIM-3 plays an active role and does not merely function as a scavenger receptor as reported for TIM-1 in kidney cells (68).

Although a role for Gal-9 in the neutrophil respiratory burst has not been reported to date, galectins have been shown to be capable of directly inducing O$_2^-$ production in primed neutrophils (69, 70). Indeed, Gal-3 has been shown to induce O$_2^-$ release in unstimulated neutrophils, albeit at micromolar concentrations (49). In this study, Gal-9 could only promote O$_2^-$ generation at supraphysiological concentrations $>50$ nM. However, a low dose of Gal-9 (50 nM) was shown to be sufficient to enhance fMLF-induced O$_2^-$ production, suggesting that Gal-9 can act as a priming agent for the NADPH oxidase at physiological concentrations. Additionally, our data show that Gal-9 is capable of inducing neutrophil degranulation via signaling through TIM-3. These results are consolidated by experiments providing evidence that Gal-9 can induce intracellular Ca$^{2+}$ mobilization, a perquisite for oxidase and degranulation functionality. Taken together, we have identified a novel role for TIM-3/Gal-9 in neutrophil function with potentially important consequences in neutrophil antimicrobial activity.

Having established a role for TIM-3/Gal-9 interactions in neutrophil activity, ensuing experiments focused on the bactericidal role of TIM-3 and Gal-9. TIM-3 has previously been implicated in bacterial killing although the proposed mechanisms of action are diverse. In a mouse model of tuberculosis infection, $M$. tuberculosis–infected macrophages increased intracellular killing following stimulation by TIM-3–expressing T cells (22). In this paradigm, Gal-9 served as a cell-surface receptor in macrophages, and TIM-3 was the ligand. Gal-9 activation by TIM-3 promoted
caspase-1 processing and release of IL-1β, which stimulated intracellular killing in an autocrine manner. In contrast, soluble TIM-3 markedly reduced E. coli killing by human peripheral blood monocytic cells (53). In this model, TIM-3 expressed in phagocytes appeared to be directly involved in phagocytosis and intracellular production of reactive oxygen and nitrogen species. In the current study, to clarify if soluble TIM-3 enhanced or blocked bacterial killing by neutrophils, neutrophils isolated from whole blood were incubated with 5 μg/ml recombinant TIM-3 fusion protein, a dose within the range employed in previous studies (22, 53). In the current study, TIM-3 treatment inhibited P. aeruginosa neutrophil-mediated killing, whereas it exerted no effect on the level of S. aureus killing. Our data suggest that TIM-3 expressed in neutrophils is directly involved in bacterial killing, in agreement with previous results linking TIM-3 function on phagocytes with E. coli killing (53). Moreover, the inclusion of

**FIGURE 8.** Gal-9–evoked enhanced P. aeruginosa killing is TIM-3 mediated. (A) Neutrophils (1 × 10^7) were incubated for 10 min in the presence or absence of 10 μg/ml TIM-3–blocking Ab (TIM-3 Ab) or mouse IgG control Ab (Con IgG). P. aeruginosa remained unopsonized or opsonized with 50 nM Gal-9 and were then incubated with neutrophils at a ratio of 1:1 for 2 or 16 min. Serial dilutions were plated on tryptic soy agar plates in triplicate. Blockade of TIM-3 reversed the enhanced killing induced by P. aeruginosa opsonization with Gal-9. Results shown are mean ± SE of n = 3 independent experiments. Percentage P. aeruginosa survival in samples treated with TIM-3–blocking Ab was not significantly different from nonopsonized bacteria. All other treatments were statistically significant. Data analyzed compared with Gal-9 unopsonized bacteria by Student t test. (B) Neutrophils from healthy individuals (HC) or PWCF (n = 3) were incubated either with either unopsonized or Gal-9 (50 nM) opsonized bacteria. Aliquots were removed at 0 and 16 min and P. aeruginosa percentage survival determined. Data shown as mean MFI ± SE of n = 3 independent experiments with neutrophils from different donors. Statistical significance calculated by Student t test, *p < 0.05, **p < 0.001. (C) P. aeruginosa was incubated with and without Gal-9 (50 and 500 nM) for 30 min and bacterial survival determined. (D and E) Flow cytometry analysis of TIM-3 membrane expression on unstimulated (Con) and IL-8–stimulated purified blood neutrophils and BALF neutrophils from PWCF (n = 3). Relative isotype control Ab, rat IgG2A, is illustrated (black filled histogram). (F) Neutrophils (1 × 10^6/ml) were incubated in PBS, 200 μg of CF BALF, or 100 nM NE at 37˚C. Levels of TIM-3 on the cell surface were measured by flow cytometry. Bar graph shows MFI peak values for each treatment. Data shown in (E) and (F) are mean ± SE; n = 3. Statistical significance calculated by Student t test. *p < 0.05, **p < 0.01 compared with control or PBS cells, respectively.
recombinant TIM-3 significantly reduced killing of serum opsonized bacteria, in line with reports on plasma levels of Gal-9. Indeed, galectins can act as pathogen recognition molecules against a wide range of microorganisms, although different affinities for specific glycan epitopes may determine the immune response in the host. For instance, both Gal-3 and Gal-9 bind to L. major poly-β-galactosyl epitopes, but only Gal-9 induced uptake of the parasite by macrophages (71). Moreover, LPS from different bacterial species has been shown to bind to Gal-3, including Klebsiella pneumonia (44), E. coli, Salmonella typhimurium (43), and, notably, P. aeruginosa (42). LPS interaction with Gal-3 appeared to occur at specific sites, including recognition of the lipid A/inner core region or the o-polysaccharide chain (44). The N-terminal part of Gal-3 has also been shown to bind specifically to the rough form of LPS (LPS devoid of side chains), and in contrast, the C-terminal part of Gal-3 specifically interacted with β-galactoside present on side chains of smooth LPS (LPS containing the o-polysaccharide chain). To the best of our knowledge, Gal-9 has not previously been reported to bind to LPS, and data demonstrating that Gal-9 bound to P. aeruginosa, but not S. aureus, corroborated the selective role of Gal-9 in P. aeruginosa uptake and killing and potentially other Gram-negative bacteria expressing LPS.

The data from this study indicated that Gal-9 had no direct effect on viability of bacteria, but Gal-9 opsonization could promote bacterial killing by neutrophils from healthy control and PWCF. This effect was achieved with 50 nM opsonization, and surprisingly, incubation with higher levels of Gal-9 did not increase bacterial killing. Concentrations of Gal-9 previously recorded in the airways are between 1 and 18 nM (35, 72), which is within the range employed in the current study. Blockade of TIM-3 abrogated the neutrophil-mediated killing of P. aeruginosa promoted by Gal-9 opsonization, confirming the implication of TIM-3 in the observed bactericidal effects. Our data suggest that TIM-3 is involved in killing of Gram-negative bacteria, in particular P. aeruginosa via interaction with Gal-9 that binds to bacterial LPS. Of note, the best intracellular killing effect and calcium flux was observed at ~2 min, yet two activation processes involving O2− and degranulation, which were measured extracellularly, were recorded up to 15 min. The discrepancy in the timing of the resultant cellular processes is likely due to the difference in intracellular and extracellular fluid volumes, and for example, the amount of protein that must be degranulated to the outside of the cell before detection by Western blotting.

We have previously shown that both TIM-3 and Gal-9 are completely absent in the adult CF lung due to proteolytic degradation (35), and in the current study, we observed reduced levels of TIM-3 on CF BALF neutrophils and healthy control cells exposed to CF BALF or NE. The lack of bacterial killing via this novel TIM-3/Gal-9 mechanism may have a negative impact on the eradication of Gram-negative bacterial infections, which may in part explain why P. aeruginosa is a successful colonizer of the CF lower airways. CF infants are initially infected with S. aureus and H. influenzae, but soon become infected with P. aeruginosa (73). Initially, these infections may be sporadic and alternate different strains, usually presenting a nonmucoid phenotype (75, 76). The median age for the onset of P. aeruginosa colonization has been traditionally established at ~10 y of age (75); however, P. aeruginosa presence in the lungs of preschool children has been reported in several studies (74, 77, 78). Interestingly, the onset of P. aeruginosa infection coincides in time with the appearance of elevated levels of NE and a concomitant decline in Gal-9 presence in BALF (35). The absence of Gal-9 and/or TIM-3 may result in impaired P. aeruginosa clearance by neutrophils and promote colonization. Therefore, early intervention with aerosolized proteolytic-resistant Gal-9 could be beneficial in preventing bacterial colonization in the CF airways, preferably in conjunction with NE inhibitors such as α-1 antitrypsin (AAT). Aerosolization of AAT has previously been shown to increase AAT levels and restore anti-NE capacity in lung epithelium lining fluid of PWCF (79). Aerosolized AAT was found to positively impact upon neutrophil-mediated killing of Pseudomonas (80), possibly by preventing cleavage of complement receptors by serine proteases (81) or by preventing cleavage of CXCR1 (82). The results of the current study further support aerosolization of AAT for maintaining neutrophil membrane levels of TIM-3.

In conclusion, our data suggest a novel role for TIM-3/Gal-9 in neutrophil function and demonstrate that TIM-3 expressed on neutrophils plays a direct role in bacterial killing. Enhanced neutrophil-mediated killing of Gal-9–opsonized Pseudomonas was observed, an antimicrobial effect perturbed in the CF airways. The rapid degradation of membrane TIM-3 by serine proteases could potentially contribute to the defective bacterial clearance observed within the CF lung despite the high neutrophilic presence.

Acknowledgments

We thank Prof. A. W. Segal and Dr. P. Behe, The Rayne Institute, Centre for Molecular Medicine, University College London, for tremendous help on TIM-3 murine studies. We also thank all of the healthy volunteers and PWCF who participated in this study.

Disclosures

The authors have no financial conflicts of interest.

References

28. Vij, N., S. Mazur, and P. L. Zeitlin. 2009. CFTR is a negative regulator of


type head of bacteriophage T4.


19. Rennert, P. D., T. Ichimura, I. D. Sizing, V. Bailly, Z. Li, R. Rennard, P. McCoon,

20. Khademi, M., Z. Ille` s, A. W. Gielen, M. Marta, N. Takazawa, C. Baecher-Allan,


32. Reeves, E. P., H. Lu, H. L. Jacobs, C. G. Messina, S. Bolsover, G. Gabella,

29. Rennert, P. D., T. Ichimura, I. D. Sizing, V. Bailly, Z. Li, R. Rennard, P. McCoon,


33. Bergin, D. A., E. P. Reeves, P. Meleady, M. Henry, O. J. McElvaney,


43. Mey, A., H. Leffler, Z. Hmama, G. Normier, and J. P. Revillard. 1996. The


19. Rennert, P. D., T. Ichimura, I. D. Sizing, V. Bailly, Z. Li, R. Rennard, P. McCoon,


34: 445–455.


73. Cystic Fibrosis Foundation Patient Registry. 2010. 2009 Annual Data Report to the Center of Directors. Cystic Fibrosis Foundation, Bethesda, MD.


